Thomas Christély is Managing Partner of ARCADUS Pharma GmbH. Mr. Christély brings more than 23 years of experience in business and corporate development and finance. He has more than 20 years of management experience at board level thereof 15 years cross-border.

His track record includes concluding multi-million dollar collaborations with AstraZeneca, Pfizer, Dainippon Sumitomo, Sankyo and other pharma and biotech companies. Mr. Christély executed - jointly with his teams - collaborations with Parexel, Quintiles and other leading clinical research organizations in the US, Canada and Germany for various phase I, II and III human clinical studies.

From 2001 until 2012 Mr. Christély was Chief Financial Officer of Silence Therapeutics AG (as of 2005 also Chief Operating Officer), a leader in RNAi therapeutics. After the reverse IPO in 2005, Mr. Christély also became the COO and later the CEO of its holding company Silence Therapeutics plc, London, listed on the AIM, London. From 1996 to 2000, he held the position of Senior VP and CFO at OXO Chemie AG, a Swiss pharmaceutical company, and founded its subsidiary OXO Chemie Inc. in San Francisco, where he stayed from 1997 to 2000.

Mr. Christély was managing partner of the investment firm Löschen & Partner, Hamburg/Moscow, from 1992 to 1995. He worked on cross-border transactions in mergers & acquisitions at Enskilda Securities Ltd., London from 1989 to 1992. After his studies in Hamburg and Geneva, he received degrees in Business Administration (equivalent to MBA) and Law from the University of Hamburg and the High Court of Hamburg, respectivley, and was admitted as attorney-at-law.